Paraoxonase 1 Gene L55M Polymorphism and Paraoxonase 1 Activity in Obstructive Sleep Apnea Patients

  • A. Płóciniczak
  • A. Baszczuk
  • A. Ludziejewska
  • H. Winiarska
  • S. Michalak
  • G. Kasprzak
  • D. Formanowicz
  • S. Cofta
  • E. WysockaEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1150)


The antioxidant enzyme paraoxonase-1 (PON1) may limit oxidative stress in the development of cardiovascular diseases (CVD) and obstructive sleep apnea (OSA). The aim of the study was to determine PON1 gene L55M polymorphism in OSA-positive and OSA-negative subjects, along with paraoxonase activity of the enzyme (PON1-act). Caucasians aged 25–75, with BMI 19.0–53.0 kg/m2 and no acute or severe chronic disorder underwent polysomnography, and OSA-negative (n = 44) and OSA-positive (n = 57) groups were established. The following parameters were assessed: arterial blood pressure and serum glucose, lipids, C–reactive protein, and homocysteine. Genomic DNA was extracted and amplified, and automatic sequencing was used to confirm the LL, LM, MM genotypes. PON1–act was measured spectrophotometrically using paraoxon as a substrate. We found that frequency of polymorphisms differed significantly between the OSA–negative and OSA–positive patients (p < 0.05). Increased PON1–act was observed in the LL–genotype versus the LM + MM–genotype in the study population (p < 0.05). PON1–act was higher in the OSA–negative compared with OSA–positive patients (p < 0.001); in general and in the subgroups presenting the LL or LM genotype. In addition, there was an inverse relationship between PON1–act and LDL–cholesterol in the entire study population. The OSA–positive group presented an inverse relationship between PON1–act and fasting glucose. We conclude that patients could benefit from the LL genotype related with higher activity of PON1. OSA pathology might decrease the enzyme activity, despite the presence of L allele.


Antioxidant activity Atherosclerosis Gene polymorphism Oxidative stress Paraoxonase enzyme Obstructive sleep apnea 


Conflicts of Interest

The authors declare no conflicts of interests in relation to this work.


  1. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo–Parmo SL, La Du BN (1998) Paraoxonase inhibits high–density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101:1581–1590CrossRefGoogle Scholar
  2. Baysal E, Taysi S, Aksoy N, Uyar M, Celenk F, Karatas ZA, Tarakcioglu M, Bilinc H, Mumbuc S, Kanlikama M (2012) Serum paraoxonase, arylesterase activity and oxidative status in patients with obstructive sleep apnea syndrome (OSAS). Eur Rev Med Pharmacol Sci 16:770–774PubMedGoogle Scholar
  3. Campo S, Sardo M, Trimarchi G, Bonaiuto M, Fontana L, Castaldo M, Bonaiuto A, Saitta C, Bitto A, Manduca B, Riggio S, Saitta A (2004) Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians. Exp Gerontol 39:1089–1094CrossRefGoogle Scholar
  4. Cofta S, Wysocka E, Piorunek T, Rzymkowska M, Batura–Gabryel H, Torlinski L (2008) Oxidative stress markers in the blood of persons with different stages of obstructive sleep apnea syndrome. J Physiol Pharmacol 59(Suppl6):183–190PubMedGoogle Scholar
  5. Danzi–Soares NJ, Genta PR, Nerbass FB, Pedrosa RP, Soares FS, César LA, Drager LF, Skomro R, Lorenzi–Filho G (2012) Obstructive sleep apnea is common among patients referred for coronary artery bypass grafting and can be diagnosed by portable monitoring. Coron Artery Dis 23:31–38CrossRefGoogle Scholar
  6. Dyugovskaya L, Lavie P, Lavie L (2002) Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 165:934–939CrossRefGoogle Scholar
  7. Flekac M, Skrha J, Zidkova K, Lacinova Z, Hilgertova J (2008) Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol Res 57:717–726PubMedGoogle Scholar
  8. Gbandjaba NY, Ghalim N, Hassar M, Berrougui H, Labrazi H, Taki H, Saile R, Khalil A (2012) Paraoxonase activity in healthy, diabetic and hemodialysis patients. Clin Biochem 45:470–474CrossRefGoogle Scholar
  9. Goswami B, Tayal D, Gupta N, Mallika V (2009) Paraoxonase: a multifaceted biomolecule. Clin Chim Acta 410:1–12CrossRefGoogle Scholar
  10. Gross ER, Ladisa JFJR, Weihrauch D, Olson LE, Kress TT, Hettrick DA, Pagelps WDC, Kersten JR (2003) Reactive oxygen species modulate coronary wall shear stress and endothelial function during hyperglycemia. Am J Phys 284:H1552–H1559Google Scholar
  11. Gupta N, Gill K, Singh S (2009) Paraoxonases: structure, gene polymorphism and role in coronary artery disease. Indian J Med Res 130:361–368PubMedGoogle Scholar
  12. Haj Mouhamed D, Ezzaher A, Mechri A, Neffati F, Omezzine A, Bouslama A, Gaha L, Douki W, Najjar MF (2012) Effect of cigarette smoking on paraoxonase 1 activity according to PON1 L55M and PON1 Q192R gene polymorphisms. Environ Health Prev Med 17:316–321CrossRefGoogle Scholar
  13. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R (2004) Structure and evolution of the serum paraoxonase family detoxifying and anti–atherosclerotic enzymes. Nat Struct Mol Biol 11:412–419CrossRefGoogle Scholar
  14. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE (1993) The molecular basis of the human serum paraoxonase polymorphisms. Nat Genet 3:73–76CrossRefGoogle Scholar
  15. Jaouad L, de Guise C, Berrougui H, Cloutier M, Isabelle M, Fultop T, Payette H, Khalil A (2006) Age–related decrease in high–density lipoproteins antioxidant activity is due to an alteration in the PON1’s free sulfhydyl groups. Atherosclerosis 185:191–200CrossRefGoogle Scholar
  16. Kallel A, Sediri Y, Sbai MH, Mourali MS, Feki M, Elasmi M, Taieb SH, Sanhaji H, Souheil O, Mechmeche R, Jemaa R, Kaabachi N (2010) The paraoxonase L55M and Q192R gene polymorphisms and myocardial infraction in a Tunisian population. Clin Biochem 43:1461–1463CrossRefGoogle Scholar
  17. Kerkeni M, Addad F, Chauffert M, Chuniaud L, Miled A, Trivin F, Maaroufi K (2006) Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease. Clin Biochem 39:821–825CrossRefGoogle Scholar
  18. Kiely JL, McNicholas WT (2000) Cardiovascular risk factors in patients with obstructive sleep apnoea syndrome. Eur Resir J 16:128–133CrossRefGoogle Scholar
  19. Koda Y, Tachida H, Soejima M, Takenaka O, Kimura H (2004) Population differences in DNA sequence variation and linkage disequilibrium at the PON1 gene. Ann Hum Genet 68:110–119CrossRefGoogle Scholar
  20. Kotani K, Kimura S, Tsuzaki K, Sakane N, Komada I, Schulze J, Gugliucci A (2008) Reduced paraoxonase 1/arylesterase activity and its post–therapeutic increase in obstructive sleep apnea syndrome: a preliminary study. Clin Chim Acta 395:184–185CrossRefGoogle Scholar
  21. Lakshmy R, Ahmad D, Abraham RA, Sharma M, Vemparala K, Das S, Reddy KS, Prabhakaran D (2010) Paraoxonase gene Q192R & L55M polymorphisms in Indians with acute myocardial infraction & association with oxidized low density lipoprotein. Indian J Med Res 131:522–529PubMedGoogle Scholar
  22. Lavie L, Vishnevsky A, Lavie P (2003) Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 27:123–128Google Scholar
  23. Michalak S, Kazmierski R, Hellmann A, Wysocka E, Kocialkowska–Adamczewska D, Wencel–Warot A, Nowinski WL (2011) Serum paraoxonase/arylesterase activity affects outcome in ischemic stroke patients. Cerebrovasc Dis 32:124–132CrossRefGoogle Scholar
  24. Morray B, Goldenberg I, Moss AJ, Zareba W, Ryan D, McNitt S, Eberly SW, Glazko G, Mathew J (2007) Polymorphisms in the paraoxonase adn endothelial nitric oxide synthase genes and the risk of early–onset myocardial infraction. Am J Cardiol 99:1100–1105CrossRefGoogle Scholar
  25. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST (2001) Paraoxonase–2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell–mediated oxidative modification of low density lipoprotein. J Biol Chem 276:44444–44449CrossRefGoogle Scholar
  26. Pasqualini L, Cortese C, Marchesi S, Siepi D, Pirro M, Vaudo G, Liberatoscioli L, Gnasso A, Schillaci G, Mannarino E (2005) Paraoxonase–1 activity modulates endothelial function in patients with peripheral arterial disease. Atherosclerosis 183:349–354CrossRefGoogle Scholar
  27. Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J (2002) Increased incidence of cardiovascular disease in middle–aged men with obstructive sleep apnea: a 7–year follow–up. Am J Respir Crit Care Med 166:159–165CrossRefGoogle Scholar
  28. Sanghera DK, Aston CE, Saha N, Kamboh MI (1998) DNA polymorphisms in two paraoxonase gene (PON1 and PON2) are associted with the risk of coronary heart disease. Am J Hum Genet 62:36–44CrossRefGoogle Scholar
  29. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J (2004) Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta–analysis of 43 studies. Lancet 363:689–695CrossRefGoogle Scholar
  30. WHO (1999) Diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus. Report no. 99. WHO, Geneva, p 2Google Scholar
  31. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V (2005) Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 353:2034–2041CrossRefGoogle Scholar
  32. Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, Watanabe G, Ishikawa K, Ikeda Y (1997) A 192arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk of coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 17:3565–3569CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG  2018

Authors and Affiliations

  • A. Płóciniczak
    • 1
  • A. Baszczuk
    • 2
  • A. Ludziejewska
    • 2
  • H. Winiarska
    • 3
  • S. Michalak
    • 4
  • G. Kasprzak
    • 2
  • D. Formanowicz
    • 1
  • S. Cofta
    • 3
  • E. Wysocka
    • 2
    Email author
  1. 1.Department of Clinical Biochemistry and Laboratory MedicinePoznan University of Medical SciencesPoznańPoland
  2. 2.Department of Laboratory DiagnosticsPoznan University of Medical SciencesPoznańPoland
  3. 3.Department of Respiratory Medicine, Allergology and Pulmonary OncologyPoznan University of Medical SciencesPoznańPoland
  4. 4.Department of Neurochemistry and NeuropathologyPoznan University of Medical SciencesPoznańPoland

Personalised recommendations